Sarcoidosis is an infiltrative disease known to affect multiple layers of the heart. Although rare, aortic valve involvement has been seen. The role of transcatheter aortic valve replacement (TAVR) has been described in amyloidosis, a well-known infiltrative disease, but not in sarcoidosis. As the awareness of cardiac sarcoidosis grows, as in amyloidosis, its impact on the aortic valve will grow too. Our review highlights the epidemiology, pathophysiology, and treatment of cardiac sarcoidosis with a discussion for TAVR in patients affected by aortic valve insult.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cpcardiol.2021.100858 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!